Dipartimento di Farmacia-Scienze del Farmaco, Via Orabona, 4, 79125 Bari, Italy.
Centro Singular Investigación Quimica Biologica e Materiales Moleculares (CIQUS), Departamento de Quimica Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
J Med Chem. 2023 Mar 23;66(6):3798-3817. doi: 10.1021/acs.jmedchem.2c01227. Epub 2023 Mar 15.
Sigma (σ) receptor subtypes, σ and σ, are targets of wide pharmaceutical interest. The σ receptor holds promise for the development of diagnostics and therapeutics against cancer and Alzheimer's disease. Nevertheless, little is known about the mechanisms activated by the σ receptor. To contribute to the exploitation of its therapeutic potential, we developed novel specific fluorescent ligands. Indole derivatives bearing the butyl-3-spiro[isobenzofuran-1,4'-piperidine] portion were functionalized with fluorescent tags. Nanomolar-affinity fluorescent σ ligands, spanning from green to red to near-infrared emission, were obtained. Compounds (σ pan affinity) and (σ selective), which displayed the best compromise between pharmacodynamic and photophysical properties, were investigated in flow cytometry, confocal, and live cell microscopy, demonstrating their specificity for the σ receptor. To the best of our knowledge, these are the first red-emitting fluorescent σ ligands, validated as powerful tools for the study of σ receptors via fluorescence-based techniques.
西格玛(σ)受体亚型,σ 和 σ,是广泛的药物靶点。σ 受体有望开发出针对癌症和阿尔茨海默病的诊断和治疗方法。然而,对于 σ 受体激活的机制知之甚少。为了促进其治疗潜力的开发,我们开发了新型的特异性荧光配体。带有丁基-3-螺[异苯并呋喃-1,4'-哌啶]部分的吲哚衍生物用荧光标记物进行了功能化。获得了从绿色到红色到近红外发射的纳摩尔亲和力的荧光 σ 配体。研究了具有最佳药效学和光物理性质折衷的化合物 (σ 泛亲和力)和 (σ 选择性),它们在流式细胞术、共聚焦和活细胞显微镜中表现出对 σ 受体的特异性。据我们所知,这些是第一批红色发射的荧光 σ 配体,已被验证为通过荧光技术研究 σ 受体的有力工具。